Clinical Study of Universal Off-the-shelf Cell Products in Patients With CD19-positive Relapsed/Refractory B-cell Hematolymphatic Malignancies.
Latest Information Update: 23 May 2025
At a glance
- Drugs UTAA-09/17-gamma-delta-T-cell-therapy PersonGen Biotherapeutics (Primary) ; Cyclophosphamide; Fludarabine
- Indications Haematological malignancies
- Focus Adverse reactions; Therapeutic Use
- Sponsors PersonGen Biotherapeutics
Most Recent Events
- 16 May 2025 Status changed from not yet recruiting to recruiting.
- 25 Oct 2023 New trial record